Literature DB >> 16328527

The 2004 World Health Organization classification of pituitary tumors: what is new?

Mubarak Al-Shraim1, Sylvia L Asa.   

Abstract

The classification of pituitary tumors is a dynamic area that changes with advances in cell biology that provide a deeper insight and clearer understanding of cell lineages and pathogenetic mechanisms. The 2004 edition of the World Heath Organization (WHO) text "Histological typing of endocrine tumors" reflects the progress that has been achieved since the previous edition of 2000. Here we review the new information and identify areas of concern for the next effort at classification of pituitary tumors.

Entities:  

Mesh：

Year:  2005        PMID： 16328527     DOI： 10.1007/s00401-005-1093-6

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN： 0001-6322            Impact factor:   17.088


  30 in total

Review 1.  Optimal management of non-functioning pituitary adenomas.

Authors:  Yona Greenman; Naftali Stern
Journal:  Endocrine       Date:  2015-07-16       Impact factor: 3.633

2.  Systematic Investigation of Expression of G2/M Transition Genes Reveals CDC25 Alteration in Nonfunctioning Pituitary Adenomas.

Authors:  Henriett Butz; Kinga Németh; Dóra Czenke; István Likó; Sándor Czirják; Vladimir Zivkovic; Kornélia Baghy; Márta Korbonits; Ilona Kovalszky; Péter Igaz; Károly Rácz; Attila Patócs
Journal:  Pathol Oncol Res       Date:  2016-12-21       Impact factor: 3.201

3.  Null cell adenomas of the pituitary gland: an institutional review of their clinical imaging and behavioral characteristics.

Authors:  James A Balogun; Eric Monsalves; Kyle Juraschka; Kashif Parvez; Walter Kucharczyk; Ozgur Mete; Fred Gentili; Gelareh Zadeh
Journal:  Endocr Pathol       Date:  2015-03       Impact factor: 3.943

Review 4.  Clinical Impact of the Current WHO Classification of Pituitary Adenomas.

Authors:  W Saeger; J Honegger; M Theodoropoulou; U J Knappe; C Schöfl; S Petersenn; R Buslei
Journal:  Endocr Pathol       Date:  2016-06       Impact factor: 3.943

5.  Prolactinoma ErbB receptor expression and targeted therapy for aggressive tumors.

Authors:  Odelia Cooper; Adam Mamelak; Serguei Bannykh; John Carmichael; Vivien Bonert; Stephen Lim; Galen Cook-Wiens; Anat Ben-Shlomo
Journal:  Endocrine       Date:  2013-11-28       Impact factor: 3.633

6.  High Ki-67 expression is associated with prolactin secreting pituitary adenomas.

Authors:  Bogdan Bălinişteanu; Anca Maria Cîmpean; Amalia Raluca Ceauşu; Ana Silvia Corlan; Eugen Melnic; Marius Raica
Journal:  Bosn J Basic Med Sci       Date:  2017-05-20       Impact factor: 3.363

Review 7.  Radiotherapy of nonfunctioning and gonadotroph adenomas.

Authors:  Andrew A Kanner; Benjamin W Corn; Yona Greenman
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

Review 8.  Modification of hormonal secretion in clinically silent pituitary adenomas.

Authors:  Tania Daems; Johan Verhelst; Alex Michotte; Pascale Abrams; Dirk De Ridder; Roger Abs
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

9.  Low expression of secreted frizzled-related protein 2 and nuclear accumulation of β-catenin in aggressive nonfunctioning pituitary adenoma.

Authors:  Youtu Wu; Jiwei Bai; Linchuan Hong; Chunhui Liu; Shengyuan Yu; Guoqiang Yu; Yazhuo Zhang
Journal:  Oncol Lett       Date:  2016-05-13       Impact factor: 2.967

10.  Selective loss of MEG3 expression and intergenic differentially methylated region hypermethylation in the MEG3/DLK1 locus in human clinically nonfunctioning pituitary adenomas.

Authors:  Roger Gejman; Dalia L Batista; Ying Zhong; Yunli Zhou; Xun Zhang; Brooke Swearingen; Constantine A Stratakis; E Tessa Hedley-Whyte; Anne Klibanski
Journal:  J Clin Endocrinol Metab       Date:  2008-07-15       Impact factor: 5.958
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.